Related Experiment Videos
Immunologic findings in tissue of thyroid carcinoma
M R Knoll1, J Teuber, H Zmierczak
1II Medical Clinic, University of Heidelberg, Mannheim, Germany.
Cancer Detection and Prevention
|January 1, 1992
Summary
Thyroid tumors express DR-antigen (DR-Ag) on epithelial cells, attracting immune cells. Thyroid-stimulating hormone (TSH) enhances this expression, suggesting a role in the immune response to thyroid cancer.
Area of Science:
- Immunology
- Endocrinology
- Oncology
Background:
- Thyroid epithelial cells (TEC) and their interaction with the immune system in thyroid carcinoma are not fully understood.
- The role of thyroid-stimulating hormone (TSH) in modulating the tumor microenvironment's immunologic behavior requires further investigation.
Purpose of the Study:
- To investigate the presence of DR-antigen (DR-Ag) positive TEC, lymphocyte (Ly) subsets, and antigen-presenting cells (APC) in thyroid carcinoma.
- To determine the influence of TSH on the immunologic behavior of thyroid tumors.
Main Methods:
- Immunohistochemical analysis of DR-Ag, APC, and Ly subsets (CD-3, CD-4, CD-8) in thyroid carcinoma and endemic goiter tissues.
- In vitro culture of TEC with TSH and/or phytohemagglutinin (PHA) to assess DR-Ag expression.
Main Results:
- DR-Ag expression was detected in most thyroid carcinomas, correlating with APC and infiltrating Ly presence.
- PHA induced DR-Ag expression, which was significantly enhanced by TSH.
- No specific Ly distribution pattern was observed across different carcinoma types.
Conclusions:
- DR-Ag expression on thyroid carcinoma cells may act as an immune-activating factor, potentially induced by local immune cells.
- The distribution of DR-Ag+ TEC and Ly suggests an individual immune response against the tumor.
- TSH's precise role as a direct or indirect immune modulator in thyroid cancer warrants further research.